Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Positive”

55 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 55 results

Large-scale testing (Phase 3)Study completedNCT02031744
What this trial is testing

The Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 530
Testing effectiveness (Phase 2)WithdrawnNCT05567055
What this trial is testing

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Who this might be right for
Non-small Cell Lung Cancer
Timothy Burns, MD, PHD
Testing effectiveness (Phase 2)Looking for participantsNCT01639508
What this trial is testing

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 86
Large-scale testing (Phase 3)Study completedNCT01662869
What this trial is testing

Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 564
Large-scale testing (Phase 3)Study completedNCT02472964
What this trial is testing

Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.

Who this might be right for
Breast Cancer
Mylan Inc. 500
Testing effectiveness (Phase 2)Study completedNCT01900652
What this trial is testing

Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 111
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Large-scale testing (Phase 3)Not Yet RecruitingNCT07136987
What this trial is testing

A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery

Who this might be right for
Tuberculosis
Open Source Pharma Foundation 1,104
Testing effectiveness (Phase 2)Looking for participantsNCT07322783
What this trial is testing

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

Who this might be right for
EGFR Positive Non-small Cell Lung CancerMET Amplification
Qingdao Central Hospital 60
Early research (Phase 1)Ended earlyNCT05435846
What this trial is testing

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer
Collin Blakely 3
Large-scale testing (Phase 3)Study completedNCT01887886
What this trial is testing

Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 10
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Testing effectiveness (Phase 2)Ended earlyNCT00611715
What this trial is testing

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 48
Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)UnknownNCT01802450
What this trial is testing

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Who this might be right for
Chronic Myeloid Leukemia
PETHEMA Foundation 18
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)UnknownNCT02897479
What this trial is testing

A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Who this might be right for
Lung Sarcomatoid Carcinoma
Hutchison Medipharma Limited 76
Early research (Phase 1)Study completedNCT02978261
What this trial is testing

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

Who this might be right for
Glioma
Beijing Pearl Biotechnology Limited Liability Company 18
Testing effectiveness (Phase 2)Looking for participantsNCT05608252
What this trial is testing

VS-6766+Abema+Fulv in Met HR+/HER- BC

Who this might be right for
Breast CancerHormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Adrienne G. Waks 63
Early research (Phase 1)Study completedNCT02296879
What this trial is testing

A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types

Who this might be right for
Solid Tumors
Young Suk Park 16
Load More Results